Biodesix (BDSX) Equity Average (2019 - 2026)

Biodesix has reported Equity Average for 8 years, with the latest figure at $3.3 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 79.12% year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2026 stood at $3.3 million (down 79.12% YoY), and the FY2025 full-year result was $9.2 million, down 27.68% from the prior year.
• Equity Average for Q1 2026 stood at $3.3 million, up from -$2.1 million in the prior quarter.
• The five-year high for Equity Average was $32.1 million in Q3 2024, with the low at -$4.2 million in Q3 2023.
• Historically, Equity Average has averaged $8.0 million across 5 years, with a median of $6.1 million in 2025.
• Annual changes were most pronounced in 2023 — Equity Average sank 276.99% — and 2025, when it jumped 3563.77%.
• Biodesix's Equity Average stood at $8.9 million in 2022, then slumped by 82.3% to $1.6 million in 2023, then soared by 1454.98% to $24.4 million in 2024, then plunged by 108.59% to -$2.1 million in 2025, then surged by 259.23% to $3.3 million in 2026.
• The last three Equity Average figures came in at $3.3 million (Q1 2026), -$2.1 million (Q4 2025), and -$292000.0 (Q3 2025), per Business Quant data.